Tocainide for refractory ventricular arrhythmias of myocardial infarction.
Oral tocainide was used as a long-term antiarrhythmic in patients with symptomatic high-grade ventricular ectopic activity refractory to conventional antiarrhythmic agents. Eleven of the 22 patients had a previous myocardial infarction (three patients had a ventricular aneurysm). Unacceptable side effects precluded long-term use of tocainide in two patients. Long-term tocainide was effect in six of the remaining patients for periods of 9 days to 42.5 months (mean 15.2 months). Eight of these nine patients responded to intravenous lidocaine prior to tocainide therapy.
D000328:Adult; D000813:Anilides / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D000974:Antibodies, Antinuclear; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006333:Heart Failure / Q000401:mortality; D006801:Humans; D007700:Kinetics; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D016677:Tocainide
D000813:Anilides; D000974:Antibodies, Antinuclear; D016677:Tocainide; D008012:Lidocaine